CSIMarket Company Name, Ticker, Industry, else..
 
Hillevax Inc   (NASDAQ: HLVX)
 
Price: $2.0900 $-0.01 -0.476%
Day's High: $2.11 Week Perf:
Day's Low: $ 2.09 30 Day Perf:
Volume (M): 2,800,100 52 Wk High: $ 0.00
Volume (M$): $ 5,852 52 Wk Avg: $0.00
Open: $2.10 52 Wk Low: $0.00



 Market Capitalization (Millions $) 105
 Shares Outstanding (Millions) 50
 Employees 22
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -71
 Cash Flow (TTM) (Millions $) -50
 Capital Exp. (TTM) (Millions $) 0

Business Description


Hillevax Inc is a technology company specializing in the development and manufacture of innovative healthcare solutions. The company focuses on researching, designing, and producing medical devices, pharmaceuticals, and biotechnology products to address various medical conditions and improve patient outcomes. Hillevax Inc has a reputation for its dedication to scientific research, commitment to quality, and staying at the forefront of technological advancements in the healthcare industry.


   Company Address: 321 Harrison Avenue Boston 2118 MA
   Company Phone Number: 213-5054   Stock Exchange / Ticker: NASDAQ HLVX


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
ALEC   -12.38%    
IOVA        28.93% 
MRNA        15.94% 
NVAX        9.03% 
STRO   -14.13%    
VXRT   -4.08%    
• View Complete Report
   



Stocks on the Move

Amid Setbacks, HilleVax Inc. Faces a Crossroads Navigating Workforce Cuts and Stagnant Shares in Biopharmas High-Stakes Arena

Published Mon, Aug 5 2024 4:04 PM UTC

HilleVax Inc Faces Tumultuous Waters: 2024 Struggles Amid Norovirus Vaccine Setbacks and Workforce Reductions In an unforgiving landscape fueled by rigorous competition and increasing economic pressures, HilleVax Inc. (NASDAQ: HLVX), a Boston-based biopharmaceutical company, is currently experiencing significant challenges in the market, trailing with a performance 12.32% be...
Management Announcement

HilleVax Takes Measures to Stem Financial Losses, Announces Workforce Reduction

Published Wed, Jul 31 2024 8:00 PM UTC


BOSTON, July 31, 2024 - HilleVax, Inc. (Nasdaq: HLVX), a clinical-stage biopharmaceutical company specializing in developing and commercializing innovative vaccines, has revealed plans to downsize its workforce in a bid to reduce operational expenses. The company intends to lay off approximately 41 employees, which amounts to around 40% of its workforce, as a strategic ...
Stocks on the Move

s, there was a notable announcement on July 22, 2024, that Hillevax successfully cleared $26.2 million in debt by repaying its loan agreement with Hercules Capital. While this m...

Published Wed, Jul 31 2024 4:12 PM UTC

Over the past quarter, Hillevax Inc (NASDAQ: HLVX) has found its shares trailing significantly behind the overall market performance. With a staggering drop of approximately 86.93% over the last four weeks, it seems the company is grappling with a tumultuous period marked by financial uncertainty, investigations, and disappointing clinical trial results. This analysis seeks ...
Stocks on the Move

HilleVax Inc Navigating Troubled Waters Amidst Regulatory and Market Headwinds

Published Sat, Jul 27 2024 6:06 AM UTC

In recent weeks, HilleVax Inc. (NASDAQ: HLVX) has found itself at the center of a tumultuous landscape, marked by regulatory scrutiny, disappointing clinical trial results, and notable shifts in investor sentiment. This convergence of challenges has created a precarious atmosphere for stakeholders and future prospects alike.On July 8, 2024, HilleVax s share price took a sign...
Stocks on the Move

HilleVax Incs Share Performance Falls Amidst Setbacks in Norovirus Vaccine Development

Published Tue, Jul 16 2024 9:41 AM UTC

HilleVax Inc, a pharmaceutical company specializing in vaccine development, has recently experienced a significant decline in their share performance. This decline can be attributed to multiple factors, including the halt of their most advanced norovirus vaccine development after a phase 2 failure and ongoing investigations and claims by investors. These setbacks have contri...



Fundamental Analysis

Valuation Current
Price to Earnings PE Ratio (TTM) -
Price to Earnings PE Ratio (Expected) -
Price to Sales (TTM) -
Price to Sales (Expected) -
Price to Book 0.71
PEG (TTM) -

Financial Strength Current
Quick Ratio 25.96
Working Capital Ratio 26.39
Leverage Ratio (MRQ) 0.18
Total Debt to Equity -
Interest Coverage (TTM) -
Debt Coverage (TTM) -

Per Share Current
Earnings (TTM) -1.44 $
Revenues (TTM) -
Cash Flow (TTM) -
Cash 3.18 $
Book Value 2.95 $
Dividend (TTM) 0 $

Efficiency Current
Revenue per Employee (TTM) -
Net Income per Employee (TTM) -3,231,682
Receivable Turnover Ratio (TTM) -
Inventory Turnover Ratio (TTM) -
Asset Turnover Ratio (TTM) -

Profitability Ratios Current
Gross Margin (MRQ) -
Operating Margin (MRQ) -
Net Margin (MRQ) -
Net Cash Flow Margin (MRQ) -
Effective Tax Rate (TTM) -

Management Effectiveness Current
Return On Assets (TTM) -
Return On Investment (TTM) -
Return On Equity (TTM) -
Dividend Yield -
Pay out Ratio (TTM) -






Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.